National Hepatitis Testing Day on 19 May is often centred on raising awareness of hepatitis B and C but it also presents an opportunity to highlight a broader, equally important issue: the need for integrated infectious disease screening.

Hepatitis rarely exists in isolation. In many patient populations, co-infections with other diseases can significantly impact diagnosis, treatment, and long-term outcomes. Expanding testing strategies beyond a single condition is essential for delivering more effective patient care.

The Overlap Between Hepatitis and Other Infections

Hepatitis B and C share common transmission routes with several other infectious diseases, particularly those spread through blood or close contact. As a result, co-infections are not uncommon.

For example:

• Hepatitis B and C frequently occur alongside HIV
• Co-infections can accelerate disease progression
• Clinical management becomes more complex when multiple infections are present

Without comprehensive testing, these overlapping conditions may go undetected, leading to incomplete diagnosis and suboptimal treatment decisions.

The Case for Broader Screening Panels

Single-disease testing can miss the bigger picture. Integrated screening approaches allow laboratories and clinicians to assess multiple conditions simultaneously, improving diagnostic efficiency and patient outcomes.

Benefits of broader screening include:

• Earlier identification of co-infections
• More informed clinical decision-making
• Reduced need for repeat patient visits and additional sampling
• Streamlined laboratory workflows

For healthcare systems, this approach supports both efficiency and improved standards of care.

The Laboratory’s Role in Integrated Diagnostics

Laboratories play a critical role in enabling comprehensive screening strategies. The ability to deliver accurate results across multiple assays is essential in supporting clinicians managing complex cases.

To achieve this, laboratories require:

• Reliable assays across different disease markers
• Consistent performance across testing platforms
• Flexible solutions that support varied testing needs
• Efficient workflows to handle increased testing demands

High-quality diagnostics ensure that expanded screening does not come at the cost of accuracy or reliability.

Supporting Comprehensive Testing Approaches

Biorex Diagnostics recognises the importance of a broader diagnostic perspective. By offering a wide range of assays across infectious disease categories, laboratories are better equipped to implement integrated screening strategies.

This approach supports:

• Multi-marker testing within a single laboratory setting
• Greater efficiency in routine diagnostics
• Improved detection of co-existing conditions
• Enhanced support for clinicians managing complex patient cases

Beyond Awareness

National Hepatitis Testing Day is not only about encouraging more people to get tested it is about improving how testing is delivered.

Expanding from single-disease testing to integrated screening models represents a significant step forward in addressing the real-world challenges of infectious disease management.

A More Complete Diagnostic Picture

Early detection remains the foundation of effective healthcare. However, true progress comes from seeing the full picture identifying not just one infection, but all relevant conditions that may affect patient outcomes.

By supporting laboratories with reliable, high-quality diagnostic solutions, Biorex Diagnostics helps enable more comprehensive testing strategies that reflect the realities of modern healthcare.

On National Hepatitis Testing Day, the message evolves: testing is essential but integrated testing is transformative.

Discover our hepatitis testing range today.